EP Patent

EP4282390A2 — Implants with controlled drug delivery features

Assigned to Glaukos Corp · Expires 2023-11-29 · 2y expired

What this patent protects

A drug delivery ocular implant (53) comprising an outer shell (54) having a first end (52) and a second end (50), the outer shell (54) being shaped to define an interior lumen (58). The implant also comprises a cap (54a) comprising a central aperture defining a region of drug rel…

USPTO Abstract

A drug delivery ocular implant (53) comprising an outer shell (54) having a first end (52) and a second end (50), the outer shell (54) being shaped to define an interior lumen (58). The implant also comprises a cap (54a) comprising a central aperture defining a region of drug release (56), the cap (54a) fitted to the first end (52) of the outer shell (54), the region of drug release (56) configured to elute a drug. The implant also comprises a membrane (60) comprising elastic properties configured to retain the cap (54a) onto the outer shell (54).

Drugs covered by this patent

Patent Metadata

Patent number
EP4282390A2
Jurisdiction
EP
Classification
—
Expires
2023-11-29
Drug substance claim
No
Drug product claim
No
Assignee
Glaukos Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.